Taltz (ixekizumab) is a prescription drug used to treat certain inflammatory conditions, including plaque psoriasis. This drug comes as a liquid solution that’s given as an injection under the skin.

When it comes to TV ads, many consumers—and doctors—claim no one wants to see them. But the actual data show few people click away when the ads run. Data collected by realtime TV ad tracker iSpot.tv ...

The new formulation significantly reduced injection site pain compared with the original. A new citrate-free formulation of Taltz ® (ixekizumab) has been made available by Eli Lilly. Taltz, an ...

In the network meta-analysis to assess the cumulative clinical benefits of biologics in psoriasis, using PASI 100 to measure the early and sustained effect of biologic medications approved for ...

Taltz (ixekizumab) is a brand-name prescription drug that treats certain types of arthritis and psoriasis. The cost of Taltz with and without insurance can depend on several factors, such as whether ...

Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz "Taltz has long delivered effective treatment with a well-established safety profile that ...

INDIANAPOLIS, June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz ® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study ...

INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus ...

TORONTO, April 2, 2021 /CNW/ - On March 29, 2021, Health Canada issued a Notice of Compliance for Taltz ® (ixekizumab) injection, 80 mg/mL, for the treatment of pediatric patients from six to less ...

Results from first network meta-analysis based on area under the curve of 52-week clinical trial data. Taltz also helped patients stay on treatment longer and have more days without additional therapy ...